公开(公告)号：US20230340140A1

公开(公告)日：2023-10-26

申请号：US18020954

申请日：2021-08-06

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL

IPC: C07K16/28 ,  A61P37/00

CPC classification number: C07K16/2896 ,  A61P37/00 ,  A61K2039/505

Abstract: The present invention concerns therapeutic uses of C5aR antagonists, particularly avdoralimab, in particular in relation to chronic inflammatory or autoimmune disorders, and in particular in inflammatory skin diseases.

公开(公告)号：US20180369373A1

公开(公告)日：2018-12-27

申请号：US15747190

申请日：2016-07-04

Applicant: INNATE PHARMA

Inventor： NADIA ANCERIZ ,  CECILE BONNAFOUS ,  ARNAUD DUJARDIN ,  CARINE PATUREL

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  G01N33/566 ,  G01N33/574

Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.

公开(公告)号：US20170291947A1

公开(公告)日：2017-10-12

申请号：US15511778

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20240368281A1

公开(公告)日：2024-11-07

申请号：US18772517

申请日：2024-07-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20230303691A1

公开(公告)日：2023-09-28

申请号：US18331966

申请日：2023-06-09

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE DENIS ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  C07K16/2818 ,  A61P35/00 ,  A61K2039/507

Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.

公开(公告)号：US20220340661A1

公开(公告)日：2022-10-27

申请号：US17852419

申请日：2022-06-29

Applicant: INNATE PHARMA

Inventor： NADIA ANCERIZ ,  MATHIEU BLERY ,  LAURENT GAUTHIER ,  CARINE PATUREL

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/569

Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

公开(公告)号：US20180030144A1

公开(公告)日：2018-02-01

申请号：US15551919

申请日：2016-02-19

Applicant: INNATE PHARMA

Inventor： STEPHANIE CHANTEUX ,  CARINE PATUREL ,  IVAN PERROT ,  LAURENT GAUTHIER

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2896 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12Y301/03005

Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US20230235060A1

公开(公告)日：2023-07-27

申请号：US18164649

申请日：2023-02-06

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

CPC classification number: C07K16/2818 ,  C07K16/2803 ,  C07K16/2827 ,  A61K39/39558 ,  C07K16/30 ,  A61K2039/507

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20210087270A1

公开(公告)日：2021-03-25

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： CARINE PATUREL ,  HELENE SICARD

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20190225703A1

公开(公告)日：2019-07-25

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： CHRISTOPHE CAUX ,  LAURENT GAUTHIER ,  NICOLAS GOURDIN ,  CHRISTINE MENETRIER-CAUX ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.